BeyondSpring Inc. — FY2016 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2016. Although the request identifies 2016 Q4, this is an annual report, not a standalone quarterly filing. Financial statements are prepared under U.S. GAAP and amounts below are in U.S. dollars.
Business context
BeyondSpring is a clinical-stage biopharmaceutical company developing cancer therapies. Its lead candidate, Plinabulin, was being studied for chemotherapy-induced severe neutropenia, advanced non-small cell lung cancer (NSCLC), and in combination with nivolumab. The company had no approved products and had generated no product revenue.
Key financial metrics
| Metric | FY2016 / Dec. 31, 2016 | Prior comparable period |
|---|---|---|
| Revenue | $0 | $0 in FY2015 |
| Research and development expense | $10.437 million | $6.282 million in FY2015 |
| General and administrative expense | $1.931 million | $1.193 million in FY2015 |
| Operating loss | $12.368 million | $7.475 million in FY2015 |
| Net loss | $12.545 million consolidated; $12.010 million attributable to BeyondSpring | $8.052 million consolidated; $7.970 million attributable to BeyondSpring |
| Basic and diluted loss per share | $0.75 loss | $0.53 loss in FY2015 |
| Operating cash flow | -$13.698 million | -$6.570 million in FY2015 |
| Cash | $11.687 million | $10.821 million at Dec. 31, 2015 |
| Total assets / liabilities | $14.908 million / $2.609 million | $10.970 million / $1.312 million |
| Total equity | $12.299 million | $9.658 million at Dec. 31, 2015 |
Working capital was approximately $12.098 million at year-end 2016, calculated as current assets less current liabilities. No long-term debt was reported on the year-end balance sheet. The filing describes prior loans as repaid, converted to equity, or retained by the former holding company in the 2015 restructuring. Operating margins are not meaningful because the company had no revenue.
Material changes versus prior period
- Net loss increased by $4.493 million year over year; operating loss increased by $4.893 million.
- R&D expense rose by $4.155 million as clinical development and trial preparation advanced. G&A expense increased by $0.738 million.
- Operating cash use more than doubled, rising from $6.570 million to $13.698 million. Financing provided $14.713 million in 2016, primarily from a $15.250 million share issuance.
- Foreign-exchange results moved from a $13,000 gain in 2015 to a $195,000 loss in 2016. Interest expense fell to zero from $532,000.
Outlook, risks, and unusual items
- Management expected year-end cash, together with the March 2017 financing, to fund operations through at least the next 24 months and through the end of 2018, based on its operating plan. It cautioned that actual cash needs could be higher and further funding may be required, particularly for the nivolumab combination program and other candidates.
- In March 2017, after the reporting period, the IPO and concurrent private placement generated approximately $48.17 million in net proceeds. The company reported using about $4.44 million of these proceeds through April 25, 2017 for clinical trials, collaboration, R&D, personnel, and G&A costs.
- Plinabulin’s prior Phase 1/2 NSCLC trial did not meet its primary endpoint of statistically significant overall-survival improvement. The reported survival and response advantages came from a 38-patient-per-arm subset and were not statistically significant (p=0.29); the company’s Phase 3 trial therefore carried substantial execution and regulatory risk.
- The company disclosed a material weakness in internal control over financial reporting, linked to insufficient U.S. GAAP and SEC-reporting expertise among finance personnel. Management described remediation steps, but disclosure controls were deemed ineffective as of December 31, 2016.
- A notable supply and regulatory dependency is BASF’s status as the sole supplier of Solutol, an excipient not previously approved by the FDA for an intravenously administered product. Failure to obtain acceptance or maintain supply could require reformulation and delay development.
- Other principal risks include continued losses and cash burn, clinical-trial failure or delay, reliance on contract manufacturers and research organizations, China regulatory and currency risks, and the possibility of dilution or unfavorable financing terms. No material legal proceedings were reported.
- The filing cover indicates the company checked “No” for having filed all required Exchange Act reports during the preceding 12 months; investors should clarify the context and any reporting implications.
Most important facts for investors to verify
- Current cash, subsequent cash burn, and whether the March 2017 proceeds support the stated runway under the updated trial plan.
- Enrollment, interim results, statistical endpoints, and regulatory feedback for the neutropenia and NSCLC trials, including whether the NSCLC subset signal is confirmed.
- Progress in resolving the financial-reporting material weakness and improving disclosure controls.
- Solutol supply continuity and regulatory acceptability, as well as manufacturing capacity and quality controls.
- Potential financing needs, dilution, and restrictions on moving funds from PRC subsidiaries to the offshore parent.